drugset / Trial / NCT00568529
Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and overall survival of the regimen of XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory gastric cancer.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-06
- Completion
- 2010-02
Outcome
Outcome not reported
Stopped (Enrollment): “There are not enough patients enrolled.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |